Sairopa develops novel treatments for cancer by modulating the patient’s immune system. Early 2021 Sairopa acquired, backed by a reputable biotech investor, a portfolio of therapeutic antibodies from an American public company. Sairopa will enter clinical testing of two of its lead compounds in Phase 1 clinical trials in 2022. The company is based in Rotterdam, the Netherlands but operates internationally & virtually. To advance our programs, we are looking for a project manager that wants to make a difference and has a pioneer’s mentality.
Company Details
- Employees
- 18
- Founded
- -
- Address
- Stationsplein 45, A4.004,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.sairopa.com
- HQ
- Rotterdam, NL
Sairopa B.v. Questions
Sairopa B.V.'s website is http://www.sairopa.com
Sairopa B.V.'s LinkedIn profile is https://nl.linkedin.com/company/sairopa-b-v
Sairopa B.V. has
18 employees.
View email and phone details for 18
employees at Sairopa B.V..
Sairopa B.V.'s industry is
Biotechnology Research
Sairopa B.V.'s top competitors are
Skylinedx Bv,
Pan Cancer T,
Van Herk Groep,
Lava Therapeutics N.v.,
Kling Biotherapeutics,
Batavia Biosciences,
Aescap,
Absano B.v.,
Acerta Pharma B.v. (A Member Of The Astrazeneca Group),
Immios B.v..
Sairopa B.V.'s categories are Biotechnology Research
Sairopa B.V.'s founding year is 2021
